09. 21. 2022

Enabling Patient Centricity by Improving Diversity in Clinical Development

Our founder and CEO, Dr Gen Li was recently invited for a discussion with Xtelligent Healthcare Media, to explore our recent data around diversity in clinical trials. The conversation raised some interesting questions about diversity and decentralization in clinical trials. We’ve been reflecting on the issues raised in the discussion, and the strategies the clinical development industry can take to ensure patients who are enrolled in trials are representative of the patients who will receive the drug in the real-world.

Read more
07. 27. 2022

New Phesi analysis shows one third of the US population is not represented in cancer clinical trials

Phesi recently released the results of our latest big data analysis, showing that 42% of US cancer trial cohorts do not include any African American patients, and 48% have no Hispanic American patients. The analysis spanned 589,295 patients participating in 6,372 US-recruiting cancer clinical trials over the past 15 years. The results highlight an urgent need to …

Read more
07. 07. 2022

Constructing a digital twin for Cytokine Release Syndrome patients following CAR-T therapy

This year marked Phesi’s first attendance as an exhibitor at ASCO, the annual meeting of professionals and exhibitors, held by the American Society of Clinical Oncology. At the event, we announced the news that Phesi has created a new digital twin for Cytokine Release Syndrome (CRS) patients following Chimeric Antigen Receptor (CAR)-T therapy, based on our analysis of 5,473 CAR-T treated patients. The news opened up some insightful conversations at the event and has created opportunities to fundamentally transform clinical research.

Read more
05. 25. 2022

Participants in breast cancer clinical trials are getting younger. What does this mean for the future of clinical trial design?

This month, Phesi’s data revealed some fundamental insights into the changing landscape of clinical trials. Our analysis of more than 2.5 million breast cancer patients found that since 2014, the number of women younger than 60 years of age participating in clinical trials has increased dramatically, from 30% to 90%. Our analysis has paved the way for some well overdue conversations about patient centricity in clinical trials as we reflect on what this finding means for trial sponsors.

Read more
04. 28. 2022

Why do nine out of ten clinical trials fail, and how can the industry learn from these mistakes?

Clinical trials are notoriously expensive, time-consuming, and often face huge setbacks. In fact, a recent report from the American Society for Biochemistry and Molecular Biology found that as many as 90% of drugs that make it to clinical trial ultimately fail – which is frustrating for sponsors, regulators, and patients.

A successful clinical trial starts at the design stage: rigorously designed and implemented clinical trials are at the heart of delivering innovative new treatments to patients. But how can the clinical development community overcome issues in planning and design trials that deliver results?

Read more